Martin H. Voss
Memorial Sloan Kettering Cancer Center
237 Papers
613 Citations
Martin H. Voss is an academic researcher from Memorial Sloan Kettering Cancer Center. The author has contributed to research in topics: Medicine & Renal cell carcinoma. The author has an hindex of 39, co-authored 186 publications. Previous affiliations of Martin H. Voss include Cornell University & University of Sydney.
Chat about Author
Papers
A Phase I, Open-Label, Multicenter, Dose-escalation Study of the Oral Selective FGFR Inhibitor Debio 1347 in Patients with Advanced Solid Tumors Harboring FGFR Gene Alterations.
Martin H. Voss,Cinta Hierro,Rebecca S. Heist,James M. Cleary,Funda Meric-Bernstam,Josep Tabernero,Filip Janku,Leena Gandhi,A. John Iafrate,Darrell R. Borger,Nobuya Ishii,Youyou Hu,Yulia Kirpicheva,Valerie Nicolas-Metral,Anna Pokorska-Bocci,Anne Vaslin Chessex,Claudio Zanna,Keith T. Flaherty,José Baselga,José Baselga +19 more
TL;DR: Preliminary efficacy was encouraging and tolerability acceptable up to 80 mg/day, which is now used in an extension part of the study and dermatologic toxicity became sometimes dose limiting beyond the DLT period at ≥80 mg/ day.
Outcomes of patients with metastatic clear-cell renal cell carcinoma treated with second-line VEGFR-TKI after first-line immune checkpoint inhibitors.
Amishi Yogesh Shah,Ritesh Kotecha,Emily Lemke,Anuradha Chandramohan,Joshua Chaim,Pavlos Msaouel,Lianchun Xiao,Jianjun Gao,Matthew T. Campbell,Amado J. Zurita,Jennifer Wang,Paul G. Corn,Eric Jonasch,Robert J. Motzer,Padmanee Sharma,Martin H. Voss,Nizar M. Tannir +16 more
TL;DR: 2L antitumour activity and tolerance comparable to historical data for 1L TKI is observed in patients with mccRCC, and forty-five percent of subjects required a dose reduction, and twenty-seven percent of patients discontinued treatment because of toxicity.
102
A Phase Ib Study of BEZ235, a Dual Inhibitor of Phosphatidylinositol 3-Kinase (PI3K) and Mammalian Target of Rapamycin (mTOR), in Patients With Advanced Renal Cell Carcinoma
Maria I. Carlo,Ana M. Molina,Yulia Lakhman,Sujata Patil,Kaitlin M. Woo,John DeLuca,Chung-Han Lee,James J. Hsieh,Darren R. Feldman,Robert J. Motzer,Martin H. Voss +10 more
TL;DR: BEZ235 twice daily resulted in significant toxicity without objective responses; further development of this compound will not be pursued in this disease.
97
Checkpoint inhibitors and other novel immunotherapies for advanced renal cell carcinoma
TL;DR: The management of advanced renal cell carcinoma has dramatically changed over the past decade andTherapies that target the vascular endothelial growth factor (VEGF) and mammalian target of rapamycin pathways have considerably expanded treatment options; however, most patients with advanced RCC still have limited overall survival.
Treatment outcome with mTOR inhibitors for metastatic renal cell carcinoma with nonclear and sarcomatoid histologies
Martin H. Voss,Diogo Assed Bastos,Christoph A. Karlo,A. Ajeti,A. Ari Hakimi,Darren R. Feldman,James J. Hsieh,Ana M. Molina,S. Patil,Robert J. Motzer +9 more
TL;DR: A subset of patients with nonclear-cell and sarcomatoid variant ccRCC subtypes benefit from mTOR inhibitors, but most have poor outcome.
86